ProCE Banner Activity

MYF2001: Phase II Trial of Imetelstat in Patients With Myelofibrosis Who are Refractory to or Relapsed on JAK Inhibition

Slideset Download
Conference Coverage
In MF patients with poor prognosis following failure of JAK inhibition, a high dose of imetelstat, an investigational telomerase inhibitor, was associated with markedly longer median OS compared with historical data.

Released: December 06, 2018

Expiration: December 05, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology